Abstract Library

#4429 Liver transplantation for pancreatic neuroendocrine tumour: A case report

Introduction: The use of liver transplantation for metastatic neuroendocrine tumours is still being explored.

Conference:

Presenting Author: Wang H

Authors: Wang H, Tan H, Zhao H, Chi Y,

Keywords: pancreatic neuroendocrine tumour, liver transplantation, STEM,

#3652 Features of the expression of TTF-1 and Cytokeratin 19 as a predictor of a less favourable prognosis of atypical lung carcinoids

Introduction: Atypical lung carcinoids are a highly heterogeneous group of tumors, some of which have more malignant potential, which makes the search for additional morphological prognostic criteria relevant.

Conference:

Presenting Author:

Authors: Gurevich L, Bondarenco E, Markarova E, Kagoniya L,

Keywords: lung carcinoid, atypical, prognosis, TTF1, cytokeratin 19,

#1258 Expressions of CK 19 and CD117 in Hepatic Metastatic Pancreatic Nonfunctional Neuroendocrine Neoplasms

Introduction: The expressions of CK19 and CD117 in pancreatic neoruendocrine neoplasms were considered dismal prognostic factors in some studies, but inconsistent in others.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Xin B, Lou W, Ji Y, Xie Y, Xu X,

Keywords: CK19, CD117, pNEN, LM, TMA,

#827 Neuroendocrine Tumors of the Pancreas Grade 2 with Ki-67 Index More Than 5% and with Expression Cytokeratin 19 are the Risk Group of Rapid Progression

Introduction: Cytokeratin 19 (CK19) is the marker of pluripotent cells of the epithelium of the pancreatic ducts, which is not detected in differentiated endocrine cells. Our experience shows that many patients with neuroendocrine tumors of the pancreas (pNET) G2 have a rapid progression of the disease a few years after diagnosis, and metastases are found most commonly in the liver.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Gurevich L, Korsakova N, Kazantseva I, Egorov A, Britvin T,

Keywords: pancreas, neuroendocrine tumors, risk factors, Ki-67, cytokeratin 19,

#593 The Combination of CK19 and KIT is a Potential Predictor for Clinical Behaviors and Postoperative Outcomes in Resectable Pancreatic Neuroendocrine Tumors

Introduction: We assumed that pNETs is a disease triggered by the re-activation of developmental signaling pathways, once again expressing KIT and CK19.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Han X, Zhao J, Ji Y, Xu X, Lou W,

Keywords: pNET, CK19, KIT,